ライフサイエンスコーパス: gynecological

1 testinal, 28.2% for hematological, 28.1% for gynecological, 24.9% for lung and bronchus, 24.9% for sa

2 n plasma were determined in 61 patients with gynecological and breast cancers and 65 female patients

3 o achieve transgene expression in a range of gynecological and breast tumor lines.

4 a partial explanation for the background of gynecological and colorectal cancer in both HNPCC and BR

5 e largest data sets worldwide to investigate gynecological and metabolic health burden in women.

6 ion resistance (DR) is implicated in various gynecological and obstetric conditions.

7 fatal toxic shock syndrome, particularly in gynecological and obstetric contexts.

8 2 were surveyed about menstrual function and gynecological and obstetrical histories before and after

9 aminations and an extensive questionnaire on gynecological and reproductive history, physical and men

10 lysis, was observed in primary human breast, gynecological, and colon carcinomas, but not in stromal-

11 tastatic potential in cancers of urogenital, gynecological, and pulmonary origin and in melanomas.

12 Participants included medical, gynecological, and radiation oncologists and patients wi

13 lon carcinoma cell lines as well as in human gynecological, breast, and central nervous system tumors

14 ide variety of human cancers, including most gynecological, breast, and colon cancers.

15 small cell lung cancer (NSCLC) (N = 187) and gynecological cancer (N = 39) patients treated with ICIs

16 95% CI, 0.36-0.71; P < .001; I2 = 86.2%) and gynecological cancer (RR, 0.76; 95% CI, 0.62-0.93; P = .

17 vival estimates and various risk factors for gynecological cancer among non-White women were analyzed

18 e about the impact of the different types of gynecological cancer and its treatment on sexual functio

19 ic survival rates among non-White women with gynecological cancer and to identify risk factors associ

20 Ovarian cancer (OC) is the most deadly gynecological cancer and unlike most other neoplasms, su

21 fts (PDXs) and clinical cases and stratifies gynecological cancer cases with worse prognosis.

22 gher gelsolin (GSN) levels in chemoresistant gynecological cancer cells compared with their sensitive

23 2010, in which 27 surgeons from 20 tertiary gynecological cancer centers in Australia, New Zealand,

24 search Institute, Cancer Australia, National Gynecological Cancer Centre, and AstraZeneca.

25 varian cancer is the fourth leading cause of gynecological cancer death among women in the United Sta

26 and specificity of 88.8% (81.2%, 94.1%) for gynecological cancer detection.

27 Those with any gynecological cancer diagnosed before or within 6 months

28 20], Functional Assessment of Cancer Therapy/Gynecological Cancer Group Neurotoxicity Questionnaire (

29 isation for Research and Treatment of Cancer Gynecological Cancer Group was motivated by conflicting

30 in sub-Saharan Africa, and is the commonest gynecological cancer in Ghana.

31 metrial carcinomas represent the most common gynecological cancer in the United States, yet the molec

32 Endometrial cancer is the most common gynecological cancer in Western industrialized countries

33 riteria in Solid Tumors [RECIST] or modified Gynecological Cancer Intergroup CA-125), toxicity, progr

34 Criteria in Solid Tumors version 1.1 and/or Gynecological Cancer Intergroup cancer antigen 125 crite

35 and to identify risk factors associated with gynecological cancer mortality by race.

36 A total of 431 pelvic CT scans from 154 gynecological cancer patients were used for this study.

37 Here, using clinical data obtained from gynecological cancer patients, tumor samples and animal

38 hensive analysis of DNA nanotherapeutics for gynecological cancer treatment, highlighting their poten

39 phedema (LEL) is a common complication after gynecological cancer treatment, which significantly redu

40 systems enhance the therapeutic efficacy of gynecological cancer treatments, but clinical translatio

41 In this cross-sectional study of female gynecological cancer trials by state, states with partic

42 Of the 1561 invasive gynecological cancer trials that met the inclusion crite

43 opment and severity of CIPN in patients with gynecological cancer were associated with the status of

44 ovarian carcinoma (HGSOC) is the most lethal gynecological cancer with few effective, targeted therap

45 Ovarian cancer is a highly lethal gynecological cancer, and its causes remain to be unders

46 s ovarian carcinoma (HGSOC), the most lethal gynecological cancer, often leads to chemoresistant dise

47 of the standard care of women diagnosed with gynecological cancer.

48 indicator of poor prognosis in patients with gynecological cancer.

49 Ovarian cancer (OC) is the most lethal gynecological cancer.

50 health disparities for non-White women with gynecological cancer.

51 s article is part of a Special Collection on Gynecological Cancer.

52 PFS in independent NSCLC cohorts and also in gynecological cancer.

53 se as a tracer (FDG)-uptake in patients with gynecological cancer.

54 Ovarian cancer is the most lethal gynecological cancer.

55 Time to cure was <=10 years for women with gynecological cancers aged <55 years; 74% of patients wi

56 improving follow-up programs for women with gynecological cancers and supporting efforts against dis

57 al cancer, no screening mechanisms exist for gynecological cancers and therefore these cancers are ty

58 Gynecological cancers are the most prevalent cancers in

59 may be independently associated with risk of gynecological cancers beyond the contribution of the ind

60 ems (DDS) enhance drug delivery for treating gynecological cancers by increasing the bioavailability

61 orrect use of tumor markers in patients with gynecological cancers can make an impact on management o

62 for as many deaths as breast cancer and all gynecological cancers combined.

63 ncer accounts for more deaths than all other gynecological cancers combined.

64 Patients with colorectal, breast, or gynecological cancers commencing chemotherapy were rando

65 Women with gynecological cancers have a residual excess risk of dea

66 ts of reducing FT on the HRQoL of women with gynecological cancers in Nigeria.

67 L) and financial toxicity (FT) of women with gynecological cancers in sub-Saharan Africa have not bee

68 reduced BRCA1 expression might predispose to gynecological cancers indirectly, by influencing ovarian

69 Gynecological cancers may originate in the ovary or fall

70 -sectional study investigated 574 women with gynecological cancers receiving care at various stages a

71 ndometrial, vaginal and/or vulvar, and other gynecological cancers were reviewed to exclude nongyneco

72 ues report the identification of a subset of gynecological cancers with repressed expression of the p

73 antly associated with the risk of breast and gynecological cancers, and it may be utilized as a valua

74 Ovarian cancer is the most lethal of all gynecological cancers, and there is an urgent unmet need

75 n cancer is the leading cause of death among gynecological cancers, but is poorly amenable to preoper

76 HGSC) results in the highest mortality among gynecological cancers, developing rapidly and aggressive

77 ge about the nature of sexual dysfunction in gynecological cancers, highlighting recent publications

78 Gynecological cancers, including ovarian, cervical, and

79 ers for overall cancer risk, particularly in gynecological cancers, precisely, HOTAIR rs1899663 G > T

80 ld Health Organization, including breast and gynecological cancers, vaginal infections, fertility, pr

81 arian cancer (EOC) is one of the most common gynecological cancers, with diagnosis often at a late st

82 remains the most common cause of death from gynecological cancers.

83 alignancy and has the worst prognosis of all gynecological cancers.

84 orm, DeltaNp73, is upregulated in breast and gynecological cancers.

85 varian cancer is a leading cause of death in gynecological cancers.

86 cancer (EOC) remains one of the most lethal gynecological cancers.

87 iated with an increased risk of death due to gynecological cancers.

88 s article is part of a Special Collection on Gynecological Cancers.

89 veral cure indicators for Italian women with gynecological cancers.

90 ve strategies against genital infections and gynecological cancers.

91 , with the highest mortality rate of all the gynecological cancers.

92 Ovarian cancer is the most deadly of all gynecological cancers.

93 ul in the management of gastrointestinal and gynecological cancers; however, there is limited informa

94 categories and HPV types from women seeking gynecological care in Tripura, northeast India.

95 lity of screening and access to high-quality gynecological care.

96 ed 18-35 years who self-referred for routine gynecological care.

97 liver disease and details of pregnancies and gynecological care.

98 potential model since mares receive intense gynecological care.

99 nt for an underlying bleeding disorder after gynecological causes are ruled out.

100 plays an important role in the regulation of gynecological cell fate as reflected in dysregulation in

101 ecific regulatory signatures compared to non-gynecological cell types.

102 d cervical HPV infection was nested within a gynecological cohort of HIV-infected women.

103 ctional anal screening study was nested in a gynecological cohort of HIV-infected women.

104 ); reproductive health factors, particularly gynecological complaints such as vaginal discharge (OR,

105 including change in pathology and unrelated gynecological complications) in the LEEP group.

106 dometriosis is a chronic, estrogen-dependent gynecological condition affecting approximately 10% of r

107 Endometriosis is a common gynecological condition with complex etiology defined by

108 logical cancers (1643 trials) or noninvasive gynecological conditions (224 trials).

109 tritional biomarkers associated with several gynecological conditions among US women with or at risk

110 , who underwent abdominal surgery for benign gynecological conditions and acted as the control group.

111 This relation among HIV, nutrition, and gynecological conditions is complex and has rarely been

112 l stages of ovarian cancer and common benign gynecological conditions were represented.

113 f endometriosis; diagnosed with other benign gynecological conditions).

114 icronutrient serum concentrations to various gynecological conditions, producing partially adjusted o

115 g for the diagnosis and management of benign gynecological conditions, with particular emphasis on re

116 he focus of a great deal of research, benign gynecological conditions-such as endometriosis, polycyst

117 trient concentrations with the prevalence of gynecological conditions.

118 at include compromised nutrition and adverse gynecological conditions.

119 Patients seen later in gynecological consultation had more severe lesions than

120 ptoms are one of the most common reasons for gynecological consultation.

121 lowed after transplantation in a specialized gynecological consultation.

122 nd examination performed at admission to the Gynecological Department excluded adnexal neoplasm.

123 Endometriosis is a chronic inflammatory, gynecological disease characterized by the presence of e

124 ic surgery did not benefit women with benign gynecological disease in terms of effectiveness or safet

125 ntial value of ER antagonists in controlling gynecological disease in the lower reproductive tracts i

126 endent, progesterone-resistant, inflammatory gynecological disease of reproductive age women.

127 Endometriosis is a common gynecological disease that affects approximately 10% of

128 Ovarian cancer is a lethal gynecological disease that is characterized by peritonea

129 Endometriosis is a highly prevalent gynecological disease with severe negative impacts on li

130 Endometriosis, a common gynecological disease, causes chronic pelvic pain and in

131 y subjects or in control subjects with other gynecological disease.

132 ut not proven, in the pathogenesis of common gynecological diseases such as endometriosis and rarer e

133 is one of the most common manifestations of gynecological diseases, and is a prime indication for hy

134 60 women with other tumors or non-neoplastic gynecological diseases.

135 Racial disparities exist in gynecological diseases.

136 vorably indicated in endometriosis and other gynecological diseases.

137 Endometriosis is a gynecological disorder affecting 6%-10% of all women in

138 Endometriosis is an incurable gynecological disorder characterized by debilitating pai

139 dometriosis is a heritable hormone-dependent gynecological disorder, associated with severe pelvic pa

140 for primary care providers to consider these gynecological disorders in their assessment of women's h

141 ontraception, and incidence of pregnancy and gynecological disorders.

142 d to cancer, neuropsychiatric, diabetes, and gynecological disorders.

143 g has important implications for more common gynecological entities with debatable pathogenesis, such

144 had a positive HPV test result in the first gynecological evaluation and 5 additional women (7.1%) b

145 Gynecological evaluation should be maintained over time,

146 n, because up to half of women with a normal gynecological evaluation will have laboratory abnormalit

147 ified in women with menorrhagia and a normal gynecological evaluation, as 11-16% of them will meet th

148 stitution entered a standardized protocol of gynecological evaluation.

149 were significantly less likely to undergo a gynecological exam after the index screening test: durin

150 tool called the Callascope to reimagine the gynecological exam, enabling clinician and self-imaging

151 Participants underwent a gynecological examination at baseline and at approximate

152 .7%) who underwent repeating screening had a gynecological examination compared with 203 566 women (2

153 Gel lubrication is routinely used during gynecological examination to prevent or reduce pain, yet

154 magnetic resonance imaging (alternating), a gynecological examination, a transvaginal ultrasonograph

155 ddition to the detailed ophthalmological and gynecological examination, anterior segment analysis was

156 203 566 women (26.2%) who did not undergo a gynecological examination.

157 PV testing, Papanicolaou smear, and thorough gynecological examinations were conducted in all the wom

158 ional attainment, pregnancy-related factors, gynecological factors, urological and gastrointestinal t

159 S-GI measures are unlikely to be affected by gynecological functioning in healthy young women.

160 sed breast, gastrointestinal, genitourinary, gynecological, head and neck, lung, lymphoma, or melanom

161 ance of eliciting a thorough obstetrical and gynecological history during cardiovascular risk assessm

162 oup with respect to age, body mass index, or gynecological history.

163 Bacterial vaginosis (BV) is the most common gynecological infection in the United States.

164 9 could induce susceptibility to urinary and gynecological infection.

165 he first description of a series of 9 severe gynecological infections (mastitis and pelvic cellulitis

166 Endometriosis is a debilitating and painful gynecological inflammatory disease affecting up to 15% o

167 Gynecological investigation was unrevealing.

168 identified cases with poor prognosis in both gynecological LMS (P = 0.00006) and nongynecological LMS

169 In gynecological LMS, a similar trend was noted but did not

170 In gynecological LMS, the coordinate expression of these fo

171 40.4% (n = 523) had gynecological malignancies (endometrial, ovarian, cervic

172 Ovarian cancer is one of the most lethal gynecological malignancies and is often associated with

173 Gastrointestinal and gynecological malignancies disseminate in the peritoneal

174 ncer is the leading cause of death among all gynecological malignancies due to the development of acq

175 in women and the leading cause of death from gynecological malignancies in the Western World.

176 the leading cause of death among women from gynecological malignancies inthe United States.

177 trial carcinoma (EC), one of the most common gynecological malignancies worldwide, remains poor, and

178 cer is one of the leading causes of death in gynecological malignancies, and the resistance to chemot

179 er, which is the leading cause of death from gynecological malignancies, is a heterogeneous disease k

180 er (OvCa) is the leading cause of death from gynecological malignancies.

181 n high levels in the plasma of subjects with gynecological malignancies.

182 ancer is the leading cause of fatality among gynecological malignancies.

183 18F-FDG-PET/CT during lymph node staging in gynecological malignancies.

184 the leading cause of death among women with gynecological malignancies.

185 ed Sates and the leading cause of death from gynecological malignancies.

186 n cancer is the leading cause of death among gynecological malignancies.

187 herapeutic intervention in major subtypes of gynecological malignancies; however, the receptor levels

188 an cancer is the leading cause of death from gynecological malignancy and has the worst prognosis of

189 Ovarian cancer is the most lethal gynecological malignancy and is characterized by periton

190 an cancer is the leading cause of death from gynecological malignancy and the fourth leading cause of

191 arcoma (UCS) is a rare and highly aggressive gynecological malignancy characterized by poor prognosis

192 lated mortality in women, is the most lethal gynecological malignancy globally.

193 of endometrial cancer (EC), the most common gynecological malignancy in developed countries.

194 cer (EOC) is the leading cause of death from gynecological malignancy in the developed world, account

195 Endometrial cancer is the most common gynecological malignancy in the developed world.

196 Endometrial cancer remains the most common gynecological malignancy in the United States.

197 Ovarian cancer is currently the most lethal gynecological malignancy in the United States.

198 Endometrial carcinoma is the most common gynecological malignancy in the United States.

199 Serous ovarian carcinoma is the most lethal gynecological malignancy in Western countries.

200 Ovarian cancer is a gynecological malignancy that is commonly treated by cyt

201 treatment of ovarian cancer, the most lethal gynecological malignancy worldwide, is not known.

202 Ovarian cancer is the most lethal gynecological malignancy, characterized by a high rate o

203 ancer (EOC), the leading cause of death from gynecological malignancy, is a poorly understood disease

204 enesis of ovarian carcinoma, the most lethal gynecological malignancy, is unknown because of the lack

205 Endometrial cancer is the most common gynecological malignancy, with 41,000 new cases projecte

206 Endometrial cancer is the most common gynecological malignancy, with more than 280,000 cases o

207 Ovarian cancer (OC) is the most deadly gynecological malignancy, with unmet clinical need for n

208 Ovarian cancer is the leading cause of gynecological malignancy-related deaths, due to its wide

209 Endometrial cancer (EC) is the most common gynecological malignancy.

210 Epithelial ovarian cancer (EOC) is a lethal gynecological malignancy.

211 l biomarker associated with life-threatening gynecological malignancy.

212 EOC) is widely recognized as the most lethal gynecological malignancy; however, its early-stage detec

213 Ovarian cancer remains the most lethal gynecological malignant tumor.

214 polymerase chain reaction (PCR) results, and gynecological manifestations of FGS in women with differ

215 Gossypol acetate (GAA), a gynecological medicine that has been repurposed as a deg

216 ter sexual risk-taking, report prevalence of gynecological morbidity (GM), and test whether moderniza

217 Uterine leiomyomata are a major source of gynecological morbidity and are 2-3 times more prevalent

218 were abdominal (n = 113), ENT (n = 71), and gynecological (n = 58) procedures.

219 at clinically can be confused with malignant gynecological neoplasms demonstrated DNA integrity index

220 represents 12 surgical specialties: general, gynecological, neurosurgical, oral, orthopedics, otolary

221 ty to develop rapid invasive infections in a gynecological-obstetrical context.

222 the German Breast Group (GBG) and the German Gynecological Oncology Breast Study Group (AGO-B) with a

223 ho underwent 1 of 10 general, urological, or gynecological operations between January 1, 2015, and Ju

224 and temporal links between neurological and gynecological operations in 857 sCJD cases referred from

225 is characteristically detected in women with gynecological or breast adenocarcinoma.

226 rent or past axis I psychiatric diagnosis or gynecological or other medical illness.

227 5), urological (OR, 1.94; 95% CI,1.08-3.49), gynecological (OR, 4.25; 95% CI, 2.31-7.82), and colorec

228 risk of mortality from malignant neoplasm of gynecological organs (2.32, 1.59 to 3.40) in cause speci

229 50, 1.40 to 4.44), and malignant neoplasm of gynecological organs (2.76, 1.79 to 4.26).

230 immune infiltration and tumors primarily of gynecological origin harbor genomic dystrophin deletions

231 a long distance signaling between tissues of gynecological origin.

232 vascular, thoracic, general, genitourinary, gynecological, orthopedics and neurosurgery, breast, hea

233 V-uninfected women with both nutritional and gynecological outcomes were analyzed from a cross-sectio

234 s, and HPV/DNA specimens were collected from gynecological outpatient departments (OPD) or in-house p

235 osis 'pelvic pain', traditionally limited to gynecological pains, has now been generalized to include

236 Gynecological pathologies account for approximately 4.5%

237 p reported greater mean symptom severity for gynecological problems (0.29 vs 0.19, P<.001), vasomotor

238 , those in the tamoxifen group reported more gynecological problems, vasomotor symptoms, leg cramps,

239 Tubal sterilization is a common gynecological procedure that may be associated with othe

240 occurs more frequently during obstetric and gynecological procedures than during most other surgical

241 um that can cause toxic shock syndrome after gynecological procedures.

242 pecially those who used hormones for various gynecological purposes.

243 ly known as Pap test, provides an accessible gynecological sample to test the value of TP53 somatic m

244 Detection and excision of tumors by a gynecological surgeon improved with SWNT image guidance

245 randomization process included 29 strata (11 gynecological surgeons at 2 campuses and 7 colorectal su

246 ho were recruited to the study by consultant gynecological surgeons from 18 UK hospitals between Febr

247 ge, 56 years; range, 18-87 years) undergoing gynecological surgery (minimally invasive procedures, 15

248 a training cohort of participants undergoing gynecological surgery for benign and malignant indicatio

249 rs) between cases undergoing neurosurgery or gynecological surgery INTERPRETATION: It is unlikely tha

250 time of either elective cesarean section or gynecological surgery.

251 rative assessments (up to 6 weeks) following gynecological surgery.

252 f outpatient opioid use following a range of gynecological surgical procedures for benign and maligna

253 ergoing general, urological, orthopedic, and gynecological surgical procedures involving skin incisio

254 A niche is associated with various gynecological symptoms including abnormal uterine bleedi

255 Gynecological symptoms may be somatic equivalents of CMD

256 e that can be broadly utilized to understand gynecological symptoms, diseases, and their relation to

257 S), breast, gastrointestinal, head and neck, gynecological, thyroid, lung and bronchus, sarcoma, geni

258 proteins, which can be reliably monitored in gynecological tissue samples.

259 and accurately distinguish between different gynecological tissue types with segmentation accuracy ex

260 ated breast cancer, although side effects in gynecological tissues are unacceptable.

261 samples capture TP53 mutation burden in the gynecological tract, presenting potential value for canc

262 l surfaces of the human gastrointestinal and gynecological tracts and causes disease in a wide range

263 tly colonizes the human gastrointestinal and gynecological tracts and less frequently causes deep tis

264 As NSAIDs are already in routine use in gynecological treatment regimens and have acceptable saf

265 The number of gynecological trials per 100 000 persons in each state.

266 on between these variables and the number of gynecological trials per 100 000 persons was measured us

267 cy expected annual loss had lower numbers of gynecological trials per 100 000 persons, which was sign

268 for detection of folate receptor-expressing gynecological tumors.

269 and their receptors in the carcinogenesis of gynecological tumors.

270 ith the highest mortality rate among all the gynecological tumors.

271 g (nonsmall cell), breast, digestive system, gynecological, urinary system, or head and neck were inc

272 General, gynecological, urological, orthopedic, and cardiac surge

273 were recruited to the study during a routine gynecological visit.

274 knowledge the importance of the frequency of gynecological visits, which we have treated as a mediato